Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;57(6):1025-1027.
doi: 10.1038/s41409-022-01664-z. Epub 2022 Apr 11.

Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center

Azra Borogovac #  1 , Amany Keruakous #  2   3 , Michelle Bycko #  2 , Jennifer Holter Chakrabarty  2 , Sami Ibrahimi  2 , Mohamad Khawandanah  2 , George B Selby  2 , Carrie Yuen  2 , Sarah Schmidt  2 , Marcus T Autry  2 , Taha Al-Juhaishi  2 , Matthew J Wieduwilt  2 , Adam S Asch  2
Affiliations

Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center

Azra Borogovac et al. Bone Marrow Transplant. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AB, AK, MB, MK, GS, CY, TA, and AA have no competing interests to disclose. JHC: Board director for ASTCT SI: Karyopharm Theraputics: Divested equity in a private or publicly traded company in the past 24 months. SS: Ad board for BMT, Karyopharm. MW: Stock: Reata. Ad boards: Servier, Gilead/Kite, BMS, Pfizer. DMC: Sorrento.

References

    1. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–42. doi: 10.1056/NEJMoa1914347. - DOI - PMC - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. doi: 10.1056/NEJMoa1804980. - DOI - PubMed
    1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48. doi: 10.1056/NEJMoa1709866. - DOI - PMC - PubMed
    1. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52. doi: 10.1016/S0140-6736(20)31366-0. - DOI - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. doi: 10.1056/NEJMoa1707447. - DOI - PMC - PubMed

MeSH terms

Substances